Investigating mechanisms of chemoresistance in triple-negative breast cancer

研究三阴性乳腺癌的化疗耐药机制

基本信息

  • 批准号:
    10747715
  • 负责人:
  • 金额:
    $ 4.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-11 至 2026-12-31
  • 项目状态:
    未结题

项目摘要

Project Summary Chemotherapy remains the standard of care for patients with triple-negative breast cancer (TNBC), which affects 20% of patients with breast cancer. However, 50% of patients with localized TNBC treated with neoadjuvant chemotherapy display residual cancer burden after treatment and up to 25% of patients who receive this treatment will suffer metastatic recurrence within five years. The poor association between chemotherapy and patient outcome emphasizes two major problems for TNBC patients: chemoresistance, where tumor cells within the local environment are protected and do not die in response to chemotherapy, and chemotherapy-induced metastasis, where chemotherapy-induced changes in tumor intrinsic properties and the tumor microenvironment drive invasion which leads to recurrence. Previous studies have demonstrated that cell migration and extracellular matrix (ECM) remodeling are associated with chemoresistant TNBC. The goal of this proposal is to understand the mechanisms by which the ECM contributes to chemoresistance and chemotherapy-induced metastasis in TNBC. We provide preliminary data that individual proteins upregulated in TNBC tumors drive resistance to chemotherapy drug Paclitaxel and that expression of Cathepsin B (CTSB), a protease which degrades these ECM proteins into small fragments, protects against the development of chemoresistance. We will dissect the mechanism by which the protease CTSB and the ECM proteins it degrades influence response to Paclitaxel in TNBC and whether these fragments can be used to track and target chemoresistance in vivo. We have also found that chemotherapy treatment leads to changes in the ECM composition of mammary tumors. Specifically, Paclitaxel treatment leads to an increased abundance of Collagen IV, an ECM protein which promote invasion and metastasis in TNBC. Our goal is to determine the cell types that secrete ECM proteins such as Collagen IV after chemotherapy treatment, determine the contribution of these ECM proteins to chemotherapy-induced metastasis, and whether these pathways can be targeted to prevent the development of recurrence. Upon successful completion of the proposed research, our contribution is expected to be an understanding of how ECM proteins upregulated in TNBC tumors contribute to chemoresistance and how chemotherapy alters the ECM to promote recurrence and metastatic dissemination. These contributions will be significant because all TNBC patients receive chemotherapy and metastatic recurrence is a current unmet clinical need. Results from these studies will provide novel conceptual insights on mechanisms of chemoresistance and chemotherapy-induced metastasis and will allow us to develop new strategies to track, predict and overcome chemoresistance in TNBC.
项目摘要 化疗仍然是三阴性乳腺癌(TNBC)患者的标准治疗, 影响了20%的乳腺癌患者然而,50%的局部TNBC患者接受 新辅助化疗显示治疗后残留的癌症负荷,高达25%的患者 接受这种治疗将在五年内出现转移性复发。之间的不良关联 化疗和患者结果强调了TNBC患者的两个主要问题:化疗抗性, 其中局部环境中的肿瘤细胞受到保护并且不会响应于化疗而死亡,以及 化疗诱导的转移,其中化疗诱导的肿瘤内在性质的变化和肿瘤细胞的增殖, 肿瘤微环境驱动侵袭,导致复发。先前的研究表明, 细胞迁移和细胞外基质(ECM)重塑与化学抗性TNBC相关。目标 这项建议的目的是了解ECM导致化疗耐药性的机制, 在TNBC中化疗诱导的转移。 我们提供的初步数据表明,在TNBC肿瘤中上调的个别蛋白质驱动了对TNBC的耐药性。 化疗药物紫杉醇和组织蛋白酶B(CTSB)表达,CTSB是一种降解这些蛋白酶的蛋白酶 ECM蛋白分裂成小片段,防止化学抗性的发展。我们将解剖 蛋白酶CTSB及其降解的ECM蛋白影响对Paclitaxin反应的机制 TNBC以及这些片段是否可用于跟踪和靶向体内化学抗性。我们还 发现化疗治疗导致乳腺肿瘤细胞外基质成分的变化。 具体而言,紫杉醇治疗导致IV型胶原蛋白丰度增加,IV型胶原蛋白是一种ECM蛋白, 促进TNBC的侵袭和转移。我们的目标是确定分泌ECM蛋白的细胞类型 如IV型胶原蛋白,确定这些ECM蛋白对 化疗诱导的转移,以及是否可以靶向这些途径以防止其发展 的复发。 在成功完成拟议的研究后,我们的贡献预计将是了解 ECM蛋白在TNBC肿瘤中的上调如何导致化疗耐药性以及化疗如何改变 ECM促进复发和转移性播散。这些贡献将是巨大的,因为 所有TNBC患者都接受化疗,并且转移复发是目前未满足的临床需求。结果 这些研究将为化学抗性机制提供新的概念性见解, 化疗诱导的转移,并将使我们能够开发新的策略来跟踪,预测和克服 TNBC中的化学抗性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Madeleine Julie Oudin其他文献

Madeleine Julie Oudin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Madeleine Julie Oudin', 18)}}的其他基金

Investigating mechanisms of chemoresistance in triple-negative breast cancer
研究三阴性乳腺癌的化疗耐药机制
  • 批准号:
    10363559
  • 财政年份:
    2022
  • 资助金额:
    $ 4.89万
  • 项目类别:
Investigating mechanisms of chemoresistance in triple-negative breast cancer
研究三阴性乳腺癌的化疗耐药机制
  • 批准号:
    10549343
  • 财政年份:
    2022
  • 资助金额:
    $ 4.89万
  • 项目类别:
Investigating the role of the extracellular matrix in metastasis and chemo-resistance
研究细胞外基质在转移和化疗耐药中的作用
  • 批准号:
    9330827
  • 财政年份:
    2016
  • 资助金额:
    $ 4.89万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 4.89万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 4.89万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 4.89万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 4.89万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 4.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了